Xperimentations.ca Bibliographie sur le diéthylamide de l`acide

le diéthylamide de l’acide lysergique (LSD)
Bibliographie sur le diéthylamide de l’acide lysergique (LSD), Xperimentations.ca
Bibliographie sur le LSD
Abraham, H.D., A.M. Aldridge et P. Gogia. The psychopharmacology of hallucinogens,
Neuropsychopharmacology, vol. 14(4), 1996, p. 285–298.
Abraham, H.D. Visual phenomenology of the LSD flashback, Archives of General
Psychiatry, vol. 40, 1983, p. 884–889.
Abraham, H.D. Psychiatric illness in drug abusers, New England Journal of Medicine, vol.
302, 1980, p. 868–869.
Abramson, H.A., M.E. Jarvik, M.R. Kaufman, C. Kornetsky, A. Levine et M. Wagner.
Lysergic acid diethylamide (LSD-25): I. Physiological and perceptual response, The
Journal of Psychology, vol. 39, 1955, p. 3–60.
Abramson, H.A., S.E. Waxenberg, A. Levine, M.R. Kaufman et C. Kornetsky. Lysergic acid
diethylamide (LSD-25): XIII. Effect on Bender-Gestalt test performance, The Journal
of Psychology, vol. 40, 1955, p. 341–349.
Aronson, H., A.B. Silverstein et M.D. Klee. Influence of LSD-25 on subjective time,
Archives of General Psychiatry, vol. 1, 1959, p. 469–472.
Batzer, W., T. Ditzler et C. Brown. LSD use and flashbacks in alcoholic patients, Journal of
Addictive Disease, vol. 18, 1999, p. 57–63.
Berrens, Z., J. Lammers et C. White. Rhabdomyolysis after LSD ingestion, Psychosomatics,
vol. 51(4), 2010, p. 356–356.e3.
Bowers, M. Jr. Psychoses precipitated by psychotomimetic drugs: A follow-up study,
Archives of General Psychiatry, vol. 34, 1977, p. 832–835.
Bowers, M. Jr. Acute psychosis induced by psychotomimetic drug abuse: I. Clinical findings,
Archives of General Psychiatry, vol. 27, 1972, p. 437–440.
Bronson, K.R., J.W. Buckholtz et D.L. Murphy. Chronic administration of serotonergic
antidepressants attenuates the subjective effects of LSD in humans,
Neuropsychopharmacology, vol. 14, 1996, p. 425–436.
Centre de toxicomanie et de santé mentale. Vous connaissez... Le LSD, 2009. Consulté sur le
http://www.camh.net/fr/About_Addiction_Mental_Health/Drug_and_Addiction_Infor
mation/lsd_dyk_fr.html.
Colace, C. Drug dreams in mescaline and LSD addiction, The American Journal on
Addictions / American Academy of Psychiatrists in Alcoholism and Addictions, vol.
19(2), 2010, p. 192.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 2 de 6
Bibliographie sur le diéthylamide de l’acide lysergique (LSD), Xperimentations.ca
Cohen, S. et A.E. Edwards. LSD and organic brain impairment, Drug Dependence, vol. 2,
1969, p. 1–4.
Krystal, J.H., L.H. Price, C. Opsahl, G.A. Ricaurte et G.R. Heninger. Chronic MDMA use:
Effects on mood and neuropsychological function?, American Journal of Drug and
Alcohol Abuse, vol. 18, 1992, p. 331–334.
Cohen, S. Lysergic acid diethylamide: Side effects and complications, Journal of Nervous
and Mental Disease, vol. 130, 1960, p. 30–40.
Earleywine, M. Mind-altering drugs: The science of subjective experience, New York,
Oxford Press, 2005.
Fantegrossi, W.E., K.S. Murnane et C.J. Reissig. The behavioural pharmacology of
hallucinogens, Biochemical Pharmacology, vol. 75, 2007, p. 17–33.
Gonzalez-Maeso, J. et S.C. Sealfon. Psychedelics and schizophrenia, Trends in
Neuroscience, vol. 32(4), 2009, p. 225–231.
Grossman, L., E. Utterback, A. Stewart, S. Gaikwad, K.M. Chung, C. Suciu et coll.
Characterization of behavioral and endocrine effects of LSD on zebrafish,
Behavioural Brain Research, vol. 214(2), 2010, p. 277–284.
Halberstadt, A.L. et M.A. Geyer. LSD but not lisuride disrupts prepulse inhibition in rats by
activating the 5-HT(2A) receptor, Psychopharmacology, vol. 208(2), 2010, p. 179–
189.
Halpern, J.H. et H.G. Pope. Hallucinogen persisting perception disorder: What do we know
after 50 years?, Drug and Alcohol Dependence, vol. 69, 2003, p. 109–119.
Halpern, J.H. et H.G. Pope. Do hallucinogens cause residual neuropsychological toxicity?,
Drug and Alcohol Dependence, vol. 53, 1999, p. 247–256.
Holsten, F. Flashbacks: A personal follow-up, Archives of Psychiatry and Neurological
Sciences, vol. 222, 1976, p. 293–304.
Iaria, G., C.J. Fox, M. Scheel, R.M. Stowe et J.J. Barton. A case of persistent visual
hallucinations of faces following LSD abuse: A functional magnetic resonance
imaging study, Neurocase: Case Studies in Neuropsychology, Neuropsychiatry, and
Behavioural Neurology, vol. 16(2), 2010, p. 106–118.
Jarvik, M.E., A.H. Abramson et M.W. Hirsch. Lysergic acid diethylamide: Effects on
attention and concentration, The Journal of Psychology, vol. 39, 1955, p. 373–383.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 3 de 6
Bibliographie sur le diéthylamide de l’acide lysergique (LSD), Xperimentations.ca
Jarvik, M.E., A.H. Abramson et M.W. Hirsch. Lysergic acid diethylamide: Effects upon
recall and recognition of various stimuli, The Journal of Psychology, vol. 39, 1955, p.
443–454.
Julien, R.M. A primer of drug action (10th ed.), New York, Worth Publishers, 2005.
Killinger, B.A., M.M. Peet et L.E. Baker. Salvinorin A fails to substitute for the
discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats,
Pharmacology, Biochemistry, and Behavior, vol. 96(3), 2010, p. 260–265.
Kornblith, A.B. Multiple drug abuse involving non-opiate, non-alcoholic substances: II.
Physical damage, long-term psychological effects and treatment approaches and
success, International Journal of Addictions, vol. 16, 1981, p. 527–540.
Kornetsky C. Relation of physiological and psychological effects of lysergic acid
diethylamide, American Medical Association: Archives of Neurology & Psychiatry,
vol. 77, 1957, p. 657–658.
Lienert, G.A. Mental age regression induced by lysergic acid diethylamide, The Journal of
Psychology, vol. 63, 1966, p. 3–11.
Lienert, G.A. Changes in the factor structure of intelligence tests produced by d-lysergic acid
diethylamide (LSD). Dans P.B. Bradley (éd.), Neuro-psychopharmacology (p. 461465), Amsterdam, Elsevier, 1959.
Maisto, S.A., M. Galizio et G.J. Connors. Drug use and abuse, Belmont (CA), Thomson
Wadworth, 2008.
McGlothlin, W.H. et D.O. Arnold. LSD revisited: A ten year follow up of medical LSD use,
Archives of General Psychiatry, vol. 24, 1971, p. 35–49.
McLellan, A.T., G.E. Woody et C.P. O’Brien. Development of psychiatric illness in drug
abusers: Possible role of drug preference, New England Journal of Medicine, vol.
301, 1979, p. 1310–1314.
Meyer, J.S. et L.F. Quenzer. Psychopharmacology: Drugs, the brain, and behaviour,
Sunderland (MA), Sinauer Associates, 2005.
Mills, J.A. Hallucinogens as hard science: The adrenochrome hypothesis for the biogenesis
of schizophrenia, History of Psychology, vol. 13(2), 2010, p. 178–195.
Minuzzi, L. et P. Cumming. Agonist binding fraction of dopamine D2/3 receptors in rat
brain: A quantitative autoradiographic study, Neurochemistry International, vol.
56(6–7), 2010, p. 747–752.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 4 de 6
Bibliographie sur le diéthylamide de l’acide lysergique (LSD), Xperimentations.ca
Moskowitz, D. Use of haloperidol to reduce LSD flashbacks, Military Medicine, vol. 136,
1971, p. 754–756.
Naditch, M.P., P.C. Alker et P. Joffe. Individual differences and setting as determinants of
acute adverse reactions to psychoactive drugs, Journal of Nervous and Mental
Disease, vol. 161(5), 1975, p. 326–335.
Paglia-Boak, A., R.E. Mann, E.M. Adlaf et J. Rehm. Drug use among Ontario students
1977–2009 (CAMH Research Document Series No. 27), 2009. Consulté sur le
http://www.camh.net.
Palenicek, T., Z. Hlinak, V. Bubenikova-Valesova, T. Novak et J. Horacek. Sex differences
in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse
inhibition, Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol.
34(4), 2010, p. 588–596.
Passie, T., J.H. Halpern, D.O. Stichtenoth, H.M. Emrich et A. Hintzen. The pharmacology of
lysergic acid diethylamide, CNS Neuroscience and Therapeutics, vol. 14, 2008, p.
295–314.
Passie, T. Psycholytic and psychedelic therapy research: An international bibliography, New
York, Laurentinus, 1985.
Romano, A.G., J.L. Quinn, L. Li, K.D. Dave, E.A. Schindler, V.J. Aloyo et coll.
Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in
the rabbit, Psychopharmacology, vol. 212(3), 2010, p. 441–448.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
Year-end 1999 emergency department data from the Drug Abuse Warning Network
(DHHS (SMA) 00-3462), Rockville (MD), National Clearinghouse for Alcohol and
Drug Information, 2000.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
Summary of findings from the 2000 National Household Survey on Drug Abuse
(DHHS (SMA) 01-3549), Rockville (MD), National Clearinghouse for Alcohol and
Drug Information, 2001.
Sloane, B. et J.W. Lovett-Doust. Psychophysiological investigations in experimental
psychoses: Results of the exhibition of d-lysergic acid diethylamide to psychiatric
patients, Journal of Mental Science, vol. 100, 1954, p. 129–144.
Stanton, M.D. et A. Bardoni. Drug flashbacks: Reported frequency in military population,
American Journal of Psychiatry, vol. 129, 1972, p. 751–755.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 5 de 6
Bibliographie sur le diéthylamide de l’acide lysergique (LSD), Xperimentations.ca
Strassman, R.J. Adverse reactions to psychedelic drugs: A review of the literature, Journal of
Nervous and Mental Disease, vol. 172, 1984, p. 577–595.
Tsuang, M.T., J.C. Simpson et Z. Kronfol. Subtypes of drug abuse with psychosis:
Demographic characteristics, clinical features, and family history, Archives of
General Psychiatry, vol. 39, 1982, p. 141–147.
Weil, A.T. Adverse reactions to marijuana: Classification and suggested treatment, New
England Journal of Medicine, vol. 282, 1970, p. 997–1000.
Young, C.R. Sertraline treatment of hallucinogen persisting perception disorder, Journal of
Clinical Psychiatry, vol. 58, 1997, p. 85.
Centre canadien de lutte contre l’alcoolisme et les toxicomanies
75, rue Albert, bureau 500 | Ottawa (Ontario) K1P 5E7 | Canada
Tél. : 613-235-4048 | Téléc. : 613-235-8101 | [email protected]
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 6 de 6